{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+Malignancy", "query": { "condition": "Advanced Solid Tumor Malignancy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 3361, "total_pages": 337, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+Malignancy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-03T17:36:25.619Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03199586", "title": "Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Pancreas Cancer", "Prostate Cancer", "Lung Cancer", "Colon Cancer", "Esophagus Cancer", "Liver Cancer", "Ovary Cancer", "Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies" ], "interventions": [ { "name": "NP-G2-044", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novita Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2017-12-21", "completion_date": "2020-05-07", "has_results": false, "last_update_posted_date": "2025-07-20", "last_synced_at": "2026-10-03T17:36:25.619Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Duarte, California • New York, New York", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03199586" }, { "nct_id": "NCT00698841", "title": "Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2009-02", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2015-12-24", "last_synced_at": "2026-10-03T17:36:25.619Z", "location_count": 15, "location_summary": "Muscle Shoals, Alabama • Casa Grande, Arizona • Corona, California + 12 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Casa Grande", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00698841" }, { "nct_id": "NCT03700294", "title": "Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ADCT-601", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ADC Therapeutics S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-12-21", "completion_date": "2019-12-11", "has_results": false, "last_update_posted_date": "2020-05-01", "last_synced_at": "2026-10-03T17:36:25.619Z", "location_count": 4, "location_summary": "Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03700294" }, { "nct_id": "NCT04185883", "title": "Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Kirsten Rat Sarcoma (KRAS) pG12C Mutation" ], "interventions": [ { "name": "Sotorasib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "RMC-4630", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Carboplatin, pemetrexed, docetaxel, paclitaxel", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "MVASI® (bevacizumab-awwb)", "type": "DRUG" }, { "name": "TNO155", "type": "DRUG" }, { "name": "IV Chemotherapy (Regimen 1)", "type": "DRUG" }, { "name": "IV Chemotherapy (Regimen 2)", "type": "DRUG" }, { "name": "BI 1701963", "type": "DRUG" }, { "name": "AMG 404", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 610, "start_date": "2019-12-17", "completion_date": "2027-12-05", "has_results": false, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-10-03T17:36:25.619Z", "location_count": 55, "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 42 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04185883" }, { "nct_id": "NCT04293094", "title": "Study of AMG 650 in Adult Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "AMG 650", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Volastra Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 66, "start_date": "2020-03-11", "completion_date": "2023-02-15", "has_results": false, "last_update_posted_date": "2023-08-24", "last_synced_at": "2026-10-03T17:36:25.619Z", "location_count": 13, "location_summary": "Los Angeles, California • Santa Monica, California • Indianapolis, Indiana + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04293094" }, { "nct_id": "NCT01375829", "title": "Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm" ], "interventions": [ { "name": "Ixabepilone", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2011-06-27", "completion_date": "2027-03-19", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-03T17:36:25.619Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01375829" }, { "nct_id": "NCT00959127", "title": "A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Advanced or Metastatic Biliary Cancer", "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "ARRY-438162 (MEK162), MEK inhibitor; oral", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2009-08", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2020-09-16", "last_synced_at": "2026-10-03T17:36:25.619Z", "location_count": 10, "location_summary": "Los Angeles, California • Aurora, Colorado • Baltimore, Maryland + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00959127" }, { "nct_id": "NCT00003242", "title": "Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "bryostatin 1", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-02", "completion_date": "2001-10", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-10-03T17:36:25.619Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003242" }, { "nct_id": "NCT01055795", "title": "Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Bevacizumab, Everolimus and LBH589", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Herbert Hurwitz", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 14, "start_date": "2010-03", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2012-12-24", "last_synced_at": "2026-10-03T17:36:25.619Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01055795" }, { "nct_id": "NCT05554380", "title": "Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2023-09-22", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-03T17:36:25.619Z", "location_count": 207, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 167 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Arroyo Grande", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05554380" } ] }